ALRN
Income statement / Annual
Last year (2023), Aileron Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Aileron Therapeutics, Inc.'s net income was -$15.73 M.
See Aileron Therapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$119,000.00 |
$169,000.00 |
$121,000.00 |
$163,000.00 |
$155,000.00 |
$218,000.00 |
$95,000.00 |
$232,000.00 |
$325,000.00 |
$9.33 M |
| Gross Profit |
-$119,000.00 |
-$169,000.00 |
-$121,000.00 |
-$163,000.00 |
-$155,000.00 |
-$218,000.00 |
-$95,000.00 |
-$232,000.00 |
-$325,000.00 |
-$9.33 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.99 M
|
$17.97 M
|
$17.01 M
|
$11.17 M
|
$17.66 M
|
$18.45 M
|
$14.24 M
|
$10.28 M
|
$7.83 M
|
$9.33 M
|
| General & Administrative
Expenses |
$11.36 M
|
$9.68 M
|
$9.60 M
|
$9.33 M
|
$12.29 M
|
$13.45 M
|
$8.77 M
|
$7.89 M
|
$5.06 M
|
$6.70 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.36 M
|
$9.68 M
|
$9.60 M
|
$9.33 M
|
$12.29 M
|
$13.45 M
|
$8.77 M
|
$7.89 M
|
$5.06 M
|
$6.70 M
|
| Other Expenses |
$928,000.00 |
$318,000.00 |
$441,000.00 |
-$800,000.00 |
$0.00 |
$0.00 |
$0.00 |
-$18.17 M |
$0.00 |
$0.00 |
| Operating Expenses |
$16.28 M |
$27.65 M |
$26.61 M |
$20.50 M |
$29.96 M |
$31.90 M |
$23.01 M |
$18.17 M |
$12.89 M |
$6.70 M |
| Cost And Expenses |
$16.28 M |
$27.65 M |
$26.61 M |
$20.50 M |
$29.96 M |
$31.90 M |
$23.01 M |
$18.17 M |
$12.89 M |
$16.03 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$587,000.00 |
$355,000.00 |
$404,000.00 |
$46,000.00 |
$13,000.00 |
$10,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$119,000.00
|
$169,000.00
|
$121,000.00
|
$163,000.00
|
$155,000.00
|
$218,000.00
|
$95,000.00
|
$232,000.00
|
$325,000.00
|
$585,000.00
|
| EBITDA |
-$15.61 M
|
-$27.48 M
|
-$26.48 M
|
-$20.33 M
|
-$29.80 M
|
-$31.33 M
|
-$23.01 M
|
-$17.94 M
|
-$12.57 M
|
-$15.44 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$544,000.00
|
$318,000.00
|
$441,000.00
|
-$661,000.00
|
$587,000.00
|
$355,000.00
|
$404,000.00
|
$46,000.00
|
$13,000.00
|
$9,999.00
|
| Income Before Tax |
-$15.73 M |
-$27.33 M |
-$26.21 M |
-$21.16 M |
-$29.37 M |
-$31.55 M |
-$22.60 M |
-$18.12 M |
-$12.88 M |
-$16.02 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$318,000.00 |
-$441,000.00 |
$661,000.00 |
-$587,000.00 |
$355,000.00 |
$34,000.00 |
$0.00 |
$0.00 |
$43,000.00 |
| Net Income |
-$15.73 M |
-$27.01 M |
-$25.76 M |
-$21.82 M |
-$28.78 M |
-$31.55 M |
-$22.60 M |
-$18.12 M |
-$12.88 M |
-$16.07 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-3.42 |
-5.95 |
-5.8 |
-12.52 |
-23.46 |
-42.81 |
-60.74 |
-33.21 |
-23.6 |
-845.63 |
| EPS Diluted |
-3.42 |
-5.95 |
-5.8 |
-12.52 |
-23.46 |
-42.81 |
-60.74 |
-33.21 |
-23.6 |
-844.96 |
| Weighted Average Shares
Out |
$4.60 M
|
$4.54 M
|
$4.44 M
|
$1.74 M
|
$1.23 M
|
$736,909.00
|
$372,153.00
|
$545,719.00
|
$545,719.00
|
$19,000.00
|
| Weighted Average Shares
Out Diluted |
$4.60 M
|
$4.54 M
|
$4.44 M
|
$1.74 M
|
$1.23 M
|
$736,909.00
|
$372,153.00
|
$545,719.00
|
$545,719.00
|
$19,015.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
